Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the week and then AFTER speaking to CEO David Dodd and the Head...
LQR House (LQR) Commits to Postpone Public Offerings for the Foreseeable Future.
LQR House Initiates Warrants Cancellation and Commits to Postpone Public Offerings for the Foreseeable Future
MIAMI BEACH, FL / ACCESSWIRE / December 20, 2023 / LQR...
GeoVax Labs (GOVX) Video Presentation.
GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers the possibility...
PharmaTher (PHRRF) Breaks Above Resistance.
We're now up 325% in just Under a Year. Last "big" News was Receiving a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)...
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...
Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the...
LQR House (LQR) +65%, Rebounding On New Clients Announcements.
The Liquor House Continues to Impress.
We called this the most interesting Company of 2023. While extreme volume and volatility remains unabated, we're now...
We’re Up 35% in Paramount.
Market Cap Increases $3 Billion Since Adding to Watch List on October 23rd. And That's a Lot of Money!
Adding Paramount (PARA) $12 to the...
Two That Doubled and Now Look Ready to Break Out.. and a Third That...
We are up 234% in Ardelyx (ARDX) $5.23 since adding it to Watch List a year ago and up 71% in Cardiol Therapeutics (CRDL)...
Tharimmune (THAR) Announces Positive Topline “Itching” Data.
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Phase 1 ex-US trial in chronic liver...















